Halozyme Therapeutics HALO Royalties — Accounts receivable, net and contract assets
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableGrossCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's royalties — accounts receivable, net and contract assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's royalties — accounts receivable, net and contract assets?
- Halozyme Therapeutics (HALO) reported royalties — accounts receivable, net and contract assets of $298.12M in Q1 2026.
- How has Halozyme Therapeutics's royalties — accounts receivable, net and contract assets changed year-over-year?
- Halozyme Therapeutics's royalties — accounts receivable, net and contract assets increased by 62.4% year-over-year, from $183.58M to $298.12M.
- What does royalties — accounts receivable, net and contract assets mean?
- This metric measures the outstanding balance of royalty payments earned but not yet collected from commercial partners, combined with recognized contract assets. It represents the company's claim to future cash inflows resulting from royalty-bearing sales that have already occurred. Monitoring this balance helps assess the timing of cash conversion and the efficiency of the royalty collection cycle.